Acrux Pharmaceuticals News and Activities

Acrux Pharmaceuticals is a company listed under the stock ticker ACXP (US).

View the org chart displaying its 8 main executives

Most searched biographies at Acrux Pharmaceuticals

• David Luci, President and Chief Executive Officer
• Carl Sailer, Director
• Jack Dean, Director

Create your alert
to follow the executive moves at Acrux Pharmaceuticals.

Acrux Pharmaceuticals has 2,340 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Regeneron Pharmaceuticals has announced the acquisition of 23andMe  (posted on May 20 2025).
• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Acrux Pharmaceuticals

• Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
• Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
• Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
• Press Releases
• Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
• Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
• Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
• Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
• Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
• Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
• View more press releases Close

Social media about Acrux Pharmaceuticals

• Acrux Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Acrux Pharmaceuticals on LinkedIn, Twitter & YouTube